Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats

被引:0
|
作者
Swarbrick, Michael M. M. [3 ,4 ,5 ]
Cox, Chad L. L.
Graham, James L. L.
Knudsen, Lotte B. B.
Stanhope, Kimber
Raun, Kirsten
Havel, Peter J. J. [1 ,2 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Nutr, One Shields Ave, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, One Shields Ave, Davis, CA 95616 USA
[3] Univ Sydney, ANZAC Res Inst, Bone Res Program, Concord, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Concord Clin Sch, Sydney, Australia
[5] Novo Nordisk AS, Malov, Denmark
基金
美国国家卫生研究院;
关键词
diabetes mellitus; food intake; growth hormone; insulin; liraglutide; obesity; TYPE-2; DIABETES-MELLITUS; INSULIN-RESISTANCE; PEPTIDE-1; ANALOG; SKELETAL-MUSCLE; GLUCOSE-TOLERANCE; OBESITY; MODEL; ADIPONECTIN; SENSITIVITY; WEIGHT;
D O I
10.1002/edm2.392
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP-1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and delay the onset of type 2 diabetes mellitus (T2DM). In UCD-T2DM rats, a model of polygenic obesity and insulin resistance, we have previously reported that daily liraglutide administration delayed diabetes onset by > 4 months. Growth hormone (GH) may exert anti-diabetic effects, including increasing beta-cell mass and insulin secretion, while disrupting GH signalling in mice reduces both the size and number of pancreatic islets. We therefore hypothesized that GH supplementation would augment liraglutide's anti-diabetic effects.MethodsMale UCD-T2DM rats were treated daily with GH (0.3 mg/kg) and/or liraglutide (0.2 mg/kg) from 2 months of age. Control (vehicle) and food-restricted (with food intake matched to liraglutide-treated rats) groups were also studied. The effects of treatment on diabetes onset and weight gain were assessed, as well as measures of glucose tolerance, lipids and islet morphology.ResultsLiraglutide treatment significantly reduced food intake and body weight and improved glucose tolerance and insulin sensitivity, relative to controls. After 4.5 months, none of the liraglutide-treated rats had developed T2DM (overall p = .019). Liraglutide-treated rats also displayed lower fasting triglyceride (TG) concentrations and lower hepatic TG content, compared to control rats. Islet morphology was improved in liraglutide-treated rats, with significantly increased pancreatic insulin content (p < .05 vs. controls). Although GH treatment tended to increase body weight (and gastrocnemius muscle weight), there were no obvious effects on diabetes onset or other diabetes-related outcomes.ConclusionGH supplementation did not augment the anti-diabetic effects of liraglutide.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Common Channel Length in Bypass Surgery Does Not Impact T2DM in Diabetic Zucker Rats
    Claudia Laessle
    Sven Michelmichel
    Goran Marjanovic
    Simon Kuesters
    Gabriel Seifert
    Ulrich T. Hopt
    Jodok Matthias Fink
    Obesity Surgery, 2017, 27 : 2090 - 2098
  • [42] Moderate Intensity Exercise Causes a Shift in the Relative Importance of the Endothelium-Dependent Relaxing Factors in Mesenteric Arteries of Male UC Davis Type-2 Diabetes Mellitus (UCD-T2DM) Rats
    Razan, Md.
    Amissi, Said
    Islam, Rifat Ara
    Rownak, Dil Afroz
    Livesey, John
    Graham, James
    Stanhope, Kimber
    Havel, Peter
    Rahimian, Roshanak
    FASEB JOURNAL, 2021, 35
  • [43] HEALTH CARE COSTS AND UTILIZATION ASSOCIATED WITH TREATMENT MODIFICATION IN TYPE-2 DIABETES MELLITUS (T2DM) PATIENTS TAKING ORAL ANTI-DIABETIC DRUGS (OADS)
    Krishnarajah, G.
    Bhosle, M. J.
    Chapman, R.
    VALUE IN HEALTH, 2009, 12 (03) : A108 - A108
  • [44] Real-world treatment patterns and adherence of first-line anti-diabetic treatments among T2dm patients using Japanese claims data
    Wang, Jocelyn Ruoyi
    Patrick, Amanda
    Mattox, Pattra
    Jaksa, Ashley
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 313 - 314
  • [45] Anti-diabetic effects of S. aegyptiaca extract on streptozotocin-nicotinamide induced type 2 diabetes rats
    Albosof, Fazel
    Hoseini, Seyed Ahmad
    Siahpoush, Amir
    Malayeri, Ali Reza
    Haghighizadeh, Mohammad Hosein
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2018, 4 (01): : 22 - 25
  • [46] The Potential of Anti-Diabetic Rakau Rongoa (Maori Herbal Medicine) to Treat Type 2 Diabetes Mellitus (T2DM) Mate Huka: A Review
    Koia, Jonni Hazeline
    Shepherd, Peter
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [47] ANTI-DIABETIC AND RENOPROTECTIVE EFFECTS OF CLADOPHORA GLOMERATA KUTZING EXTRACT IN HIGH FAT DIET WITH STREPTOZOTOCIN-INDUCED TYPE 2 DIABETIC RATS
    Srimaroeng, Chutima
    Ontawong, Atcharaporn
    Pongchidecha, Anchalee
    Chatsudthipong, Varanuj
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 50 : E177 - E178
  • [48] Anti-Diabetic Effects ofBerberis kansuensisExtract on Type 2 Diabetic Rats Revealed by1H-NMR-Based Metabolomics and Biochemistry Analysis
    Du, Huan
    Li, Qi
    Yi, Huan
    Xu, Tong
    Xu, Xin-Mei
    Kuang, Ting-Ting
    Zhang, Jing
    Huang, An-Qing
    Fan, Gang
    CHEMISTRY & BIODIVERSITY, 2020, 17 (10)
  • [49] Hepatitis B/C Don't Affect the Pioglitazone Effects in Type 2 Diabetic Patients Treated with Other Oral Anti-Diabetic Agents
    Lin, Knu-Der
    Shin, Shyi-Jang
    He, Sin-Ru
    Li, Mei-Yue
    Chang, Yu-Hung
    Hsiao, Pi-Jung
    DIABETES, 2009, 58 : A526 - A526
  • [50] Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats
    Songyan Yu
    Yu Cheng
    Linxi Zhang
    Yaqi Yin
    Jing Xue
    Bing Li
    Zhengyuan Gong
    Jieqing Gao
    Yiming Mu
    Stem Cell Research & Therapy, 10